In our HER2-positive breast cancer patients treated with T-DM1, PFS was 10 months, which is similar to the 9.6 months observed in the EMILIA study and longer than the 6.2 months observed in the TH3RESA study, which included patients who had received a greater number of prior treatment lines. Here, ERBB2 is linked to breast cancer.